Our findings are in agreement with previous studies, in which a global and keratinocyte-specific knockout of the IL-36 receptor (21, 23), or anti-IL-36R treatment (30, 36) was sufficient to effectively prevent IMQ-induced psoriasis-like skin inflammation. The gene discussed is IL1RL2; the disease is psoriasis.